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Background. The objective of this study was to examine the epidemiology, natural history, and prognostic factors of combined
hepatocellular and cholangiocarcinoma (cHCC-CC) using population-based registry. Methods. The Surveillance, Epidemiology,
and End Results Program database (1973–2004) was used to identify cases of cHCC-CC. Multivariable logistic regression was used
to evaluate factors associated with cancer-directed surgery (CDS). The inﬂuence of CDS on cancer speciﬁc survival was evaluated
using Kaplan-Meier curves and Cox proportional hazards modeling. Results. A total of 380 cases of cHCC-CC were identiﬁed,
which account for approximately 0.87% of primary liver tumors. Of all patients, 69.8% of patients had regional or distant stage;
65.6% of patients had poorly or undiﬀerentiated histology. Only 44.9% of patients with localized disease, received CDS. By logistic
regression analysis, being widowed, advanced stage, and earlier diagnosis year were associated with lower rate of utilization of
CDS. In multivariate analysis, tumor stage, receipt of CDS, and recent year of diagnosis were found to be signiﬁcant predictors
for cancer-speciﬁc survival. Conclusions. Patients with localized cHCC-CC who are selected for CDS were strongly associated with
improved survival. However, many patients with localized tumors did not receive potentially curative cancer-directed surgery.
Further study is warranted to address the barriers to the delivery of appropriate care to these patients.
1.Introduction
Combined hepatocellular and cholangiocarcinoma (cHCC-
CC) is an uncommon subtype of primary liver cancer [1,
2]. The disease was ﬁrst described in 1949 by Allen and
Lisa and has been deﬁned as the intimate intermingling
of both a HCC component and CC component (2). Two
histopathological classiﬁcation schemes have been proposed
(1,2). Allen and Lisa [1] described three groups, type A with
HCC and CC present at diﬀerent sites within the same liver,
and type B with HCC and CC present at adjacent sites and
mingle with continued growth, and type C with HCC and
CC are combined in the same tumor. Goodman et al. [2]
categorized cHCC-CC into three types: (i) collision type, (ii)
transitional type, and (iii) ﬁbrolamellar type. Kim et al. [3]
and Zhang et al. [4] proposed that cHCC-CC is a distinct
type of primary liver carcinoma, which is morphologically
and phenotypically intermediate between HCC and CC
and may be derived from hepatic progenitor cells with
the bipotential to diﬀerentiate into both hepatocytic and
cholangiocytic lineages.
Because of the rarity of cHCC-CC, previously published
literature has been based on case series and anecdotal
experiences [3–14], with largest case series include thirty
cases. The majority case series so far were reported from
Asia. Most of these reports were histopathological studies,
thedemographicfeaturesandclinicalbehaviorofthisdisease
remain ill-deﬁned, and the outcomes of these patients are
varied in a number of studies. For example, the reported
results of surgical resection from single institution have been
inconsistent [10, 15–19]. In this study, we take advantage of
the vast amount of data collected by the SEER Program to
examine the largest series of cHCC-CC reported to date. We
examine the incidence, natural history, utilization of cancer-
directed surgery (CDS) as well as prognostic factors that
might aﬀect the survival for cHCC-CC.2 Journal of Oncology
2. Methods
2.1. Data Source. In 1973, the SEER registry program was
established to identify all new cancer cases diagnosed within
7 geographic areas [20]. Since 1973, the SEER Program has
expanded several times to improve representative sampling
of minority groups as well as to increase the total sampling of
cases to allow for greater precision. The original SEER 9 reg-
istries included Atlanta, Connecticut, Detroit, Hawaii, Iowa,
New Mexico, San Francisco-Oakland, Seattle-Puget Sound,
and Utah. By 1975, SEER included 9 geographic regions, 5
states (Connecticut, Hawaii, Iowa, New Mexico, and Utah)
and 4 metropolitan areas (San Francisco-Oakland, Seattle-
Puget Sound, Detroit, and Atlanta). In 1992, four additional
registries were added to form the SEER 13 registries, which
included the SEER 9 registries, plus Los Angeles, San Jose-
Monterey, rural Georgia, and the Alaska Native Tumor
Registry.Morerecently,in2000,datafromgreaterCalifornia,
Kentucky, Louisiana, and New Jersey were added to the SEER
13 Program to form the SEER 17 registries. SEER 9, 13, and
17 registries cover approximately 9.5%, 13.8%, and 26.2%
of the total U.S. population, respectively [20]. Data for this
study were obtained from SEER
∗Stat public-use data ﬁles
available from the National Cancer Institute. For incidence
analyses, registry data were linked to total U.S. population
data from 1969 to 2003.
2.2. Study Population. The cases of cHCC-CC were extracted
from the SEER on the basis of anatomic site (ICD-O-2
codes C22.0–22.1) and histological type (ICD-O code 8180)
for those patients ﬁrst diagnosed and/or treated between
January 1973 and December 2004. A total of 42,654 patients
with hepatobilliary neoplasms were identiﬁed in the SEER
17 registries, among them, 380 patients were found with
cHCC-CC. Cases identiﬁed at the time of autopsy or by
death certiﬁcate only (24 cases) were excluded from survival
analyses.
2.3. Variables. Patients’ social demographic characteristics
(i.e., age, race/ethnicity, and marital status) and tumor grade
and stage at the time of diagnosis, were determined from the
SEER database.
Because there is no AJCC (The American Joint Com-
mittee on Cancer) staging system for cHCC-CC, general
summary stage was used [21]. This system classiﬁes patients
as having local, regional (extension into adjacent tissues or
nodal involvement), or distant disease. The World Health
Organization’s standard grading system was used with four
separate categories (well, moderately well, poorly diﬀerenti-
ated, and undiﬀerentiated). For analysis purpose, they were
groupedintolowgrade(well,moderatelywelldiﬀerentiated)
and high grade (poorly diﬀerentiated, and undiﬀerentiated).
In SEER database, any treatment that is given to
modify, control, remove or destroy primary or metastatic
cancer tissue is considered to be cancer-directed surgery
(CDS). CDS was deﬁned in this study as surgical resection
(hepatectomy), transplantation, local regional therapy (such
as radiation frequency ablation, chemoembolazation, and
embolization), and unknown surgery, based on values for
Table 1: Age-adjusted incidence rate of combined hepatocellular
and cholangiocarcinoma of the liver (cHCC-CC) per 100,000
populations.
Age-adjusted incidence rate per 100,000 (95% CI)
SEER 9 (1973–1991)
Overall 0.03 (0.02–0.04)
Men 0.05 (0.03–0.07)
Women 0.02 (0.01–0.03)
White 0.03 (0.02–0.04)
Black 0.02 (0.02–0.04)
Other 0.07 (0.03–0.12)
SEER 13 (1992–1999)
Overall 0.03 (0.02-0.03)
Men 0.04 (0.01–0.03)
Women 0.02 (0.01-0.02)
White 0.03 (0.02-0.03)
Black 0.03 (0.00–0.03)
American Indian 0.00 (0.00–0.03)
Asian 0.03 (0.00–0.03)
SEER 17 (2000–2003)
Overall 0.03 (0.02-0.03)
Men 0.04 (0.01–0.03)
Women 0.02 (0.01-0.02)
White 0.03 (0.02-0.03)
Black 0.03 (0.01–0.07)
American Indian 0.00 (0.00–0.15)
Asian 0.03 (0.00–0.06)
SEER: surveillance, epidemiology, and end results.
CI: conﬁdence interval.
site-speciﬁc surgery and surgery of the primary site codes
within the database [21]. Since only few patients received
local regional therapy, we grouped these patients together
withpatientsunderwentunknownsurgerytogetheras“other
surgery”.
2.4.StatisticalAnalysis. Byusinglinkedpopulationﬁles,age-
adjusted incidence rates and their 95% conﬁdence intervals
(CIs) were calculated for cHCC-CC for all patients, for men
and women separately, and for each of the 3 broad categories
of race (whites, blacks, and other) and in three time periods.
Discrete data are reported as frequencies and compared
by chi-square tests. Continuous data are reported as mean
± SD and compared by Student’s t-test. Multivariate logistic
regression analyses were used to determine the factors
associated with receipt of cancer-directed surgery. Survival
duration was measured by the Kaplan-Meier method and
compared by the log rank test. Multivariable Cox pro-
portional hazards model was used to identify independent
predictors of long-term cancer speciﬁc death.
SEER
∗Stat 6.2.4 (Surveillance Research Program,
National Cancer Institute) was used for incidence analyses
[20]. All other statistical calculations were performed by
SPSS 12.0 (Apache Software Foundation 2000). SurvivalJournal of Oncology 3
Table 2: Characteristics of 380 patients with combined hepatocel-
lular and cholangiocarcinoma of the liver (cHCC-CC) diagnosed
between January 1973 and December 2004.
Characteristics N (%) CDS No. CDS P value
Gender
Male 245 (64.5%) 49 196 .61
Female 135 (35.5%) 30 105
Race
Black 43 (11.3%) 5 38 .09
White 291 (76.6%) 60 231
Others 46 (12.1%) 14 32
Civil Status
Married 222 (58.4%) 59 163 .01
Divorced/Separated 37 (9.7%) 7 30
Single 52 (13.7%) 6 45
Widowed 57 (15%) 7 51
Unknown 12 (3.2%) 0 12
Grade
Well diﬀerentiated 9 (2.4%) 1 8 <.00001
Moderately diﬀerentiated 34 (8.9%) 17 17
Poorly diﬀerentiated 70 (18.4%) 21 49
Undiﬀerentiated 12 (3.2%) 2 10
Unknown 255 (67.1%) 38 217
SEER Stage
Localized 98 (25.8%) 44 54 <.0001
Regional 97 (25.5%) 22 75
Distant 130 (34.2%) 11 119
Unknown 55 (14.5%) 2 53
Year of diagnosis
1973–1988 154 (40.5%) 14 140 <.0001
1989–2004 226 (59.5%) 65 161
Cancer Directed Surgery
Yes 79 (20.8%) 79 0 <.0001
No 301 (79.2%) 0 301
Radiation Therapy
Yes 22 (5.8%) 4 18 .55
No 354 (93.2%) 75 279
Unknown 4 (1.0%) 0 4
SEER: surveillance, epidemiology, and end results.
durations calculated by SPSS. Comparative diﬀerences were
considered statistically signiﬁcant when the P value was
<.05.
3. Results
3.1. Frequency and Incidence. Between 1973 and 2004, a total
of 380 patients with cHCC-CC were identiﬁed from 42,654
patients with hepatobilliary neoplasms, which consisted of
0.87% of all patients with hepatobillary cancers. A constant
age-adjusted incidence of 0.03 per 100,000 was observed in
these three time periods. Detailed incidence data by time
period, gender, and race are included in Table 1.
3.2. Patient and Tumor Characteristics. Table 2 includes the
patient and tumor characteristics of study cohort. Of the
380 patients with cHCC-CC identiﬁed in the SEER database,
there was male predominance with a male-to-female ratio
of 1.8:1. The mean age of patients with cHCC-CC was 64
± 12 years (median age 65 years, with a range of 19 to 98
years). The majority of patients (76.6%) were white. African
American accounted for 43 cases (11.03%). Other ethnicities
accounted for 46 cases (12.11%).
Staging information were not available for 55 (14.5%)
patients. Of the remaining 325 patients, 98 (25.8%) were
classiﬁed as localized stage; 97 (25.5%) were classiﬁed as
regional stage; and 132 (34.2%) were classiﬁed as distant
stage. 82 of 125 (65.6%) patients whose histology informa-
tion available had poorly or undiﬀerentiated histology.
3.3. Treatment. Cancer-directed surgery was performed for
79 (20%) patients, among them, 20 patients underwent liver
transplantation, 40 patients underwent partial hepatectomy,
5 patients underwent local surgery (4 patients received
radiofrequency ablation (RFA) and 1 patient received per-
cutaneous ethanol injection (PEI)), and the rest of 14
patients underwent unknown surgery. A total of 301 (79.1%)
patients were treated nonsurgically. Radiation therapy was
performed in a total 22 (5.8%) of patients, in 4 (1.1%) of
22 patients, radiation was used as an adjuvant to surgery
(Table 2).
In a logistic regression analysis, marital status, tumor
stage, and year of diagnosis were identiﬁed as independent
predictors of receiving CDS. The patients who were wid-
owed,patientswithadvancedstageandthosewhowerediag-
nosed before 1989, were less likely receiving CDS (Table 3).
In a separate analysis restricted to patients with local and
regional disease, the above factors remained independent
predictors of CDS.
3.4. Survival Analysis. The mean followup duration of the
entire cohort was 8.4 months. A total of 341 of 380 (89.7%)
patients died during the followup period.
For survival analysis, we excluded the cases that were
identiﬁed at autopsy or on the basis of death certiﬁcates
only. A total of 356 patients were included in cancer-speciﬁc
survivalanalysis.Themedianoverallsurvivalforallcaseswas
4 months (95% CI 3–5).
Figure 1 presents the cancer speciﬁc survival rates
according to patient and tumor characteristics. Cancer-
speciﬁc survival rates for entire cohort at 1-, 3-, and 5-year
were 26.5%, 12.4%, and 9.2%, respectively, (Figure 1(a)).
The 1-, 3-, and 5-year cancer-speciﬁc survival rates for
patients with local and regional stage tumor were 56.3%,
29.0%, 22.1%, 25.3%; 9.6%, and 4.8%, respectively, and
for patients with distant stage tumor were 6.1%, 1.5%,
and 0%, respectively, (Figure 1(b)). There was a signiﬁcant
diﬀerence in survival between patients who underwent CDS
(transplantation, resection or other surgery) versus those did
not (P<. 0001) (Figure 1(c)). The outcomes of patients with
cHCC-CC were signiﬁcantly improved for patients who were
diagnosed in later years (1989–2004) compared to those in
earlier years (1973–1988) (Figure 1(d)).4 Journal of Oncology
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Figure 1: (a) Cancer-speciﬁc survival for overall patients with combined hepatocellular and cholangiocarcinoma of the liver (cHCC-CC).
(b)Cancer-speciﬁcsurvivalrateofpatientsaccordingtoSEERstage.P<. 0001forLocalizedversusRegionalversusDistantstage.(c)Cancer-
speciﬁc survival rate of patients with localized disease according to treatment. P<. 0001 for transplantation versus resection versus other
surgery∗ versus no surgery. (d) Cancer-speciﬁc survival rate of patients according to year of diagnosis. ∗Other surgery: local surgery plus
unknown surgery.
Table 4 presents the result of multivariate survival anal-
yses using Cox proportional hazard model. After adjusting
for the demographic, clinical, and treatment-related fac-
tors, tumor stage, receiving CDS, and year of diagnosis
were identiﬁed as independent predictors of cancer-speciﬁc
survival. Compared to patients with localized disease,
patients with regional and distant disease had 1.62 and
2.5 fold increased risk of dying, respectively. The most
important predictor of outcome was CDS. Patients who
receive cancer directed surgery had signiﬁcant decrease
in the risk of dying than those patients who did not.
(Transplantation versus no CDS, HR = 0.25; hepatec-
tomy versus no CDS, HR = 0.26; other surgery (local
treatment and unknown surgery) versus no CDS, HR =
0.28).
4. Discussion
The reported frequency of combined tumors in series of
primary hepatic malignancies varies widely, from 1.0–4.7%
[1, 2, 11, 15]. In this study, cHCC-CC accounted for approx-
imately 0.87% of primary liver tumors during study period,
which is lower than what was reported in single institution
studies [13]. “Referral bias” may contribute to the observed
higher incidence rates in the single institution studies, which
usually were from tertiary hospitals and referral centers.
Patients with rare histology subtypes are more likely to
visit referral centers for second opinion; pathologists in
tertiary centers usually have more opportunity seeing these
cases and having expertise to identify these cases, compare
with community counterparts. Therefore, the incidence rateJournal of Oncology 5
Table 3: Multivariate Logistic Regression Analysis of Factors
Associated with Cancer Directed Surgery.
Characteristics Group OR (95% CI) P value
Age 1.00 (0.97–1.03) .95
Gender Female 1.00
Male 0.57 (0.29–1.12) .10
Race
White 1.00
Black 0.33 (0.11–1.02) .053
Other 0.99 (0.43–2.32) .99
SEER Stage
Localized 1.00
Regional 0.32 (0.16–0.64) .001
Distant 0.12 (0.05–0.27) <.0001
Unstaged 0.05 (0.01–0.21) <.0001
Grade
Low grade 1.00
High grade 0.63 (0.24–1.63) .34
Unknown 0.42 (0.18–0.99) .05
Civil Status
Married 1.00
Widowed 0.22 (0.07–0.66) .007
Divorced/Separated 0.71 (0.24–2.08) .53
Diagnosis Year 1973–1988 1.00
1989–2004 2.90 (1.38–6.12) .005
Radiation No 1.00
Yes 2.60 (0.76–8.92) .13
OR: odds ratio; CI: conﬁdence interval; low grade: well diﬀerentiated/mod-
erately diﬀerentiated; high grade: poorly diﬀerentiated/undiﬀerentiated;
SEER: surveillance, epidemiology, and end results.
found in a population-based study, which include wide
spectrum of hospitals, are more likely to reﬂect the true
incidence of this rare tumor.
Similar with previous studies, most of patients with
cHCC-CCpresentedwithhighhistologicalgradetumorsand
advanced stage disease at the time of presentation (Table 2).
Our ﬁndings, along with others [22], supports the notion
that cHCC-CC represents a distinct, aggressive subtype
o fl i v e rc a n c e r[ 4–11]. These ﬁndings of subtype-related
diﬀerences in liver cancer have signiﬁcant implications:
better therapy of liver cancer is more likely to be achieved
by investigating each subtype of liver cancer separately rather
thangroupingthemalltogether.Asourunderstandingofthe
genetic basis for cancer grows, it is likely that liver cancer will
be subdivided into ever ﬁner categories.
Surgery is the only treatment oﬀering the possibility
of a cure. The main treatment goal should be complete
excision with negative margins and limited impact on
liver function. In our cohort, only 20% of all patients
received CDS. This likely reﬂects their advanced stage on
presentation. The majority of patients unfortunately were
not candidates for potential curative CDS. In addition less
than half of the patients with localized disease underwent
CDS (Table 2) raises a concern whether cancer-directed
surgery was underused in this population. The ﬁndings of
disparity of CDS utilization in cHCC-CC are similar with
ﬁndings in studies in HCC [23, 24], eﬀorts should be made
Table 4: Cox proportional multivariate analysis of factors associ-
ated with cancer-speciﬁc mortality.
Characteristics Group HR (95% CI) P Value
Age 1.00 (0.99–1.01) .56
Gender
Male 1.00
Female 1.27 (0.93–1.71) .14
Race
White 1.00
Black 1.41 (0.93–2.13) .10
Others 1.36 (0.91–2.03) .13
SEER Stage
Localized 1.00
Regional 1.59 (1.10–2.33) .018
Distant 2.50 (1.70–3.61) <.0001
Grade
Low 1.00
High 1.45 (0.90–2.32) .13
Unknown 1.02 (0.66–1.57) .94
Civil Status
Married 1.00
Widowed 1.21 (0.81–1.83) .36
Divorced/Separated 0.96 (0.59–1.54) .85
Single 1.01 (0.68–1.49) .96
Unknown 0.61 (0.31–1.24) .17
Diagnosis Year
1973–1988 1.00
1989–2004 0.81 (0.60–1.09) .16
Radiation
No 1.00
Yes 0.82 (0.50–1.38) .47
Cancer Directed
Surgery
No 1.00
Transplantation 0.25 (0.13–0.50) <.0001
Resection 0.26 (0.15–0.44) <.0001
Other Surgery 0.28 (0.15–0.53) <.0001
HR: hazard ratio; CI: conﬁdence interval; low grade: well diﬀerentiated/
moderately diﬀerentiated; high grade: poorly diﬀerentiated/undiﬀerentia-
ted; other surgery: local surgery plus unknown surgery; SEER: surveillance,
epidemiology, and end results.
to reduce these disparities. The patients diagnosed between
1989 and 2004 were almost three times more likely to
receiveCDS,incomparisontothosediagnosedbetween1973
and 1988. This encouraging trend of increasing utilization
CDS is in line with the recent advances in radiologic
diagnosis [25, 26] and a shift towards an earlier stage at
diagnosis [22, 27], and advances in liver surgery technique
[14, 28, 29].
Although the role of liver transplantation in the man-
agement of HCC or cholangiocarcinoma is well deﬁned
[30, 31], data about the role of liver transplantation in the
management of cHCC-CC are lacking [32]. Our study repre-
sented the largest series of surgical management of patients
with cHCC-CC. At present, liver transplantation and resec-
tion are the only potential curative therapy for cHCC-
CC, therefore, surgery should be considered in patients
when complete resection is possible. Because, liver resection
carries considerable operative risk; poor performance status
and comorbidities may have precluded some patients from
resection.6 Journal of Oncology
Currently, there is no literature available address-
ing impact local regional treatment options on survival
speciﬁcally on cHCC-CC. Transarterial chemoembolisation
(TACE) and percutaneous treatments such as percutaneous
ethanol injection (PEI) and radiofrequency ablation (RFA)
are widely used treatments for unresectable HCC and
postresection recurrence [33, 34]. However, many cHCC-
CCs are less vascular and much more ﬁbrotic than HCC,
and thus are less likely to respond to TACE or PEI [35]. Our
ﬁndings suggest RFA is useful in selected patients; however,
the small numbers of the patients underwent this therapy
and the short duration of followup, makes any conclusions
unreliable, and more research is required to conﬁrm this
ﬁnding.
Consistent with single institution studies, the prognosis
of this disease was poor [15, 17, 18], the median cancer
speciﬁc survival for the patients with distant disease was
2 months (range 0–31 months). We did, however, observe
a signiﬁcant improvement in the outcome of patients with
cHCC-CC over time (Figure 1(d)). Since there was no
eﬀective chemotherapy for liver cancer during the study
period [36], the better outcomes likely reﬂect the advance
in surgical techniques, better perioperative management and
supportive care [14, 28, 29].
Ourﬁndingsshouldbeinterpretedwithinthelimitations
of the study. Although we adjusted for diﬀerences in
demographicandtumorfactors,residualconfoundingmight
stillbepresent.Unlikesingle-institutionstudies,theaccuracy
ofstaging andpathologic diagnosis withina nationalregistry
may vary widely across the institutions. In addition, SEER
data did not allow us to examine surgical volume, and
patient’scomorbidities,allofwhichmayinﬂuencesurvivalin
cancer patients. However, the use of cancer speciﬁc survival
rather than overall survival in our study has modiﬁed the
limitation to some degree.
Strengths of this study include the populations-based
design and the large sample size. Having large sample size
is of particular importance for analysis of rare tumors such
as cHCC-CC, where it is nearly impossible for a single
institution to collect enough cases to make meaningful
analysis regarding important prognostic factors.
5. Conclusions
TheﬁndingsofthisstudyconﬁrmedthatCDSwasassociated
with statistically signiﬁcant increase in cancer-speciﬁc sur-
vival. However, fewer than 50% patients with localized dis-
ease received CDS. Further study is warranted to explore and
address the potential barriers to the delivery of appropriate
care to these patients.
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